Latest California Healthline Stories
The Trump administration’s policy shift on Title X family planning funds is likely to make birth control harder to get and more expensive for low-income women. It will also shift funds from organizations like Planned Parenthood to the Obria Group, which does not give women hormonal contraceptives or condoms in its clinics.
An encounter with a cat led to rabies shots and provided yet another illustration of how confusing, contrary and expensive the American health care system is.
California’s stem cell agency, created by a $3 billion bond measure 15 years ago, is almost out of money. Its supporters plan to ask voters for even more funding next year, even though no agency-funded treatments have been approved for widespread use.
A small health center in Goshen, Ind., near the border with Michigan, puts “listening to patients’ stories” first. “The rest is housekeeping.”
Tennessee company’s Medicare billings for urine tests were examined by Kaiser Health News in 2017.
Regenexx, which runs a string of clinics, says stem cell injections can save employers a lot of money, but critics say there’s no proof.
Margot Sanger-Katz of The New York Times, Joanne Kenen of Politico and Paige Winfield Cunningham of The Washington Post join KHN’s Julie Rovner to discuss the Trump administration’s efforts to curtail federally funded research using fetal tissue, the backlash from former Vice President Joe Biden’s support for the anti-abortion Hyde Amendment and how health policy intersects with both trade and immigration policy.
While Missouri’s final abortion clinic may stop providing the procedure this week, women in the state had already been seeking care in neighboring states as regulations increasingly limited abortion access.
Under the rule that took effect this year, Medicare will lower payments for clinic visits performed at hospital-owned facilities to a rate that is equivalent to what it pays an independent doctor. Federal officials expect the move will save the government $380 million this year.
Critics are concerned about the explosion in controversial stem cell procedures offered by clinics — and, increasingly, respected hospitals.